Internet Enduring Material sponsored by the Stanford University School of Medicine. Presented by the Department of Medicine at the Stanford University School of Medicine.
In this Stanford Department of Medicine Grand Rounds presentation, experts discuss the effects of COVID-19 on the gastrointestinal tract and liver.
Prior to the main presentation, there were COVID inpatient updates. Also, COVID-19 Convalescent Plasma update. The presenters discussed the impact of COVID-19 on the GI tract and liver. 60% of SARS infected individuals had evidence of liver impairment and GI symptoms were also common.
Based on a study of 204 patients, 5-/5% had digestive symptoms, including lack of appetite, diarrhea, vomiting and higher rates of abnormal ALT/AST.
Where are we with endoscopy in the era of COVID-19? Endoscopy units have reopened with mitigation protocols. Presenters Reviewed the CDC list for persons at higher risk for severe infection, including those with immunocompromised states, obesity, Type 2 diabetes, liver disease and other conditions. Presenters reviewed the presentations of liver involvement in COVID-19 and talked about the liver biopsy findings for infected patients. Liver transplantation has been interrupted by COVID-19. Discussed the factors associated with COVID-19 related deaths using OpenSAFELY. Predictors of mortality in CLD and COVID-19 were discussed. A federal committee provided a recommendation that men limit their alcohol consumption to one drink per day during the COVID outbreak, to reduce their risks.
